Miner and colleagues compared a fragment of tau protein measured in blood with brain changes observed after death. The study asked whether people with advanced chronic traumatic encephalopathy, or CTE, had a stronger blood signal. The comparison also shows how much a small set of early cases and overlapping brain pathology can influence what researchers learn.

THE SHORT READ
  • Of 21 former male football players who donated their brains, three had no CTE, two had low-stage disease and 16 had high-stage disease at autopsy.
  • Median eMTBR-tau was 0.021 pg/mL in the high-stage group and 0.001 pg/mL in the group with no CTE.
  • The highest subgroup median occurred among people who also had intermediate or high Alzheimer disease neuropathologic change. The study did not establish a clinical cutoff.
THE STUDY AT A GLANCEBlood eMTBR-tau and CTE at autopsy · Miner et al.
Paper date
19 November 2026
Sample
21 former American football players with paired blood and autopsy data
Comparison
CTE stage at autopsy and blood eMTBR-tau during life

Original publication: 19 Nov 2026 · The date above refers to this brief.

THE NUMBERS, IN CONTEXT

How many donors contributed to each CTE stage group?

donors

No CTE3
Low-stage CTE2
High-stage CTE16
021
Counts from Table 1. The comparison table reports the median concentrations for these groups.
THE EXPERIMENT, EXPLAINED

How a candidate blood marker is compared with pathology

  1. Collect blood during life

    Use the closest available research sample before death.

  2. Examine donated brain tissue

    Classify CTE stage and assess other pathology.

  3. Compare the groups

    Compare concentrations by stage and check results after removing cases with intermediate or high ADNC.

Press-News reading diagram based on the primary study.

Follow the blood sample to the reference measurement

The authors selected former football players with a research blood sample and a completed brain autopsy. They used the blood sample taken closest to death. For part of the sample, they intentionally included donors with confirmed CTE so they could study more cases. The fraction of donors with CTE describes this selected case series.

Source 1 ↗

Early and advanced cases offer different amounts of evidence

There were 16 high-stage cases and two low-stage cases. That is 88.9% high-stage among the 18 CTE cases in the research sample. The median blood concentration was 0.021 pg/mL in the high-stage group and 0.001 pg/mL in the two-person low-stage group. Assessing whether early cases can be distinguished reliably would require many more donors with early pathology and comparable participants without it.

Source 1 ↗

Alzheimer disease pathology changed the context

Five participants had CTE and intermediate or high Alzheimer disease neuropathologic change, or ADNC. Their median eMTBR-tau was 0.082 pg/mL. The median was 0.009 pg/mL for the 11 donors with high-stage CTE without intermediate or high ADNC. The authors also reported that a high-stage CTE association persisted when they excluded the five donors with ADNC. The groups were small and could differ in other ways, including age.

Source 1 ↗

A larger tau study answered a different question

Brum and colleagues examined eMTBR-tau in 728 participants across two autopsy and two brain imaging cohorts. The study connected the blood signal with advanced tau pathology using different reference measurements. Together, the papers raise a question for future work. How well does the signal distinguish CTE from other conditions that can also produce tau tangles?

Source 1 ↗Source 2 ↗

What would establish the accuracy of a blood marker?

A validation study would recruit a broader sample, prespecify a threshold and compare the blood result with pathology across early and advanced cases. It would also include donors with Alzheimer disease pathology and no CTE. That design could estimate how often the assay identifies CTE and how often a result is positive in someone with another condition.

Source 1 ↗
TRACE THE EVIDENCE

The comparison depends on stage, selection and other pathology

Original journal article. Checked the case selection, methods, Tables 1 and 2, results, comparison with Alzheimer disease pathology and limitations.

01Does this sample establish the population prevalence of CTE?

What was observed
The selected donor study included 18 CTE cases and three without CTE.
Where the conclusion stops
Some donors were deliberately included to enrich the number of cases. Population prevalence requires a representative denominator.

Source 1 · Methods, Sample and Table 1

02What contributed to the highest median concentration?

What was observed
The subgroup with CTE and intermediate or high Alzheimer disease neuropathologic change had the highest reported median.
Where the conclusion stops
Larger comparison groups are required to determine specificity for CTE.

Source 1 · Results, Table 2 and Limitations

Numbers you can inspect

MeasureValue & unitOrigin & method
Donors21 peopleReported Former American football players with blood and autopsy results.
Source 1 · Methods and Table 1
Donors with CTE18 peopleReported CTE was confirmed on neuropathologic evaluation.
Source 1 · Table 1
Donors without CTE3 peopleReported Reference count in the case series.
Source 1 · Table 1
Low-stage CTE2 peopleReported One stage I and one stage II case.
Source 1 · Table 1
High-stage CTE16 peopleReported Eight stage III and eight stage IV cases.
Source 1 · Table 1
High-stage share of CTE cases88.9 percentCalculated 16 divided by 18 times 100, rounded to one decimal.
Source 1 · Table 1
High-stage group median0.021 pg/mLReported Reported median, IQR 0.006 to 0.038.
Source 1 · Table 2
No-CTE group median0.001 pg/mLReported Reported median in three donors.
Source 1 · Table 2
CTE with intermediate or high ADNC5 peopleReported Subgroup with co-occurring pathology.
Source 1 · Results and Table 2
Median with CTE and intermediate or high ADNC0.082 pg/mLReported Median in the five-donor subgroup.
Source 1 · Table 2
Median with high-stage CTE without intermediate or high ADNC0.009 pg/mLReported Median in the eleven-donor subgroup.
Source 1 · Table 2
Separate Brum et al. study728 peopleReported 521 autopsy participants and 207 tau-PET participants.
Source 2 · Brum et al. Abstract

Compare the actual experiments

These studies answer different questions. Read the unit and endpoint before comparing results.

StudyUnit & settingReadoutInterpretation boundary
Tau assay and reference measurements

Source 2 · Brum et al. Abstract

Brain donors and tau-PET participantsBlood eMTBR-tau compared with pathology or imagingAssay performance depends on the condition and the reference measurement under study.
An association and a useful clinical endpoint

Source 1 · Miner et al. Discussion and Limitations

Autopsy groups and surrogate outcomes across studiesTau concentration and tissue pathologyA measurable signal still needs validation for a defined clinical use.
Download evidence table (CSV)

The export includes claims, available numbers, methods and source locations. It contains our reading notes and published summaries; it is not raw participant data or an independent reanalysis.

Evidence update · 21 Nov 2026
First publication. Any calculations in this brief use reported figures. The reading notes identify possible follow-up questions. AI source check; no human editorial or clinical review.

CONNECT THE EVIDENCE

The stage-by-stage comparison in the 21 donors

Autopsy findingDonorsMedian eMTBR-tau, pg/mL (IQR)
No CTE30.001 (0.001 to 0.001)
Low-stage CTE20.001 (0.001 to 0.002)
High-stage CTE160.021 (0.006 to 0.038)

Group sizes and medians come from Table 2. The IQR describes the middle half of measured values within each group.

READER QUESTIONS

Your questions, answered

Does 18 of 21 give a rate for all former football players?

The study includes donors selected through research and brain donation. Some were included because they had confirmed CTE. The count describes the study sample.

Could the study tell how well the marker detects early CTE?

There were two low-stage cases. The authors identify reliable evaluation of early disease as a question for larger studies.

What does ADNC mean in the table and article?

ADNC is Alzheimer disease neuropathologic change. The highlighted subgroup had intermediate or high ADNC along with CTE.

What does the second study add?

Brum and colleagues assessed how the assay relates to tau pathology in separate autopsy and imaging cohorts. That helps motivate tests of whether it distinguishes the cause of the tau signal.

LIMITATIONS

Limits of this interpretation

  • The case series was selected through research participation and brain donation. All donors were men and former American football players.
  • There were just two low-stage cases and three comparison donors without CTE. The sample was too small for age adjustment.
  • The study lacked an Alzheimer disease comparison group without CTE. Reliable diagnostic accuracy estimates would require a broader sample.
SOURCE NOTES

Sources & transparency

  1. Miner, Stein, McKee et al. (2026) — Plasma eMTBR-tau as a Biomarker for Chronic Traumatic Encephalopathy Tau Tangle Neuropathology

    Original journal article. Checked the case selection, methods, Tables 1 and 2, results, comparison with Alzheimer disease pathology and limitations. · Accessed 21 Nov 2026

    DOI: 10.1001/jama.2026.24780
  2. Brum, Janelidze, Singh et al. (2026) — A Plasma eMTBR-Tau Immunoassay for Detection of Advanced Insoluble Tau Pathology

    Original study, checked the abstract and cohort counts as a separate comparison for eMTBR-tau in autopsy and PET cohorts. · Accessed 21 Nov 2026

    DOI: 10.1001/jama.2026.25143

Prepared and source-checked with AI for Press-news Team. The source notes identify the material available during preparation. The article received no human editorial or clinical review. The source list supports the reported results and the calculations shown.

Source check: AI source check — primary research and stated source limits

Clinical review: Not applicable to this educational guide

Suggest a correction